PONV

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

Heron TherapeuticsNC - Cary

1 program

Aprepitant InjectionPhase 41 trial

Active Trials

NCT07639723Not Yet Recruiting350Est. Aug 2027

Acacia PharmaUK - Cambridge

3 programs

APD421Phase 31 trial

APD421- Amisulpride for IV injectionPhase 31 trial

Active Trials

NCT02337062Completed1,147Est. Sep 2015

NCT01991821Completed368Est. Jan 2014

NCT01991860Completed364Est. Jan 2014

Qilu PharmaceuticalChina - Jinan

1 program

AmisulpridePHASE_31 trial

Active Trials

NCT05822713Unknown516Est. Dec 2023

EisaiChina - Liaoning

1 program

Palonosetron onlyPHASE_41 trial

Active Trials

NCT00952133Completed118Est. Apr 2011

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

Heron TherapeuticsAprepitant Injection

EisaiPalonosetron only

Qilu PharmaceuticalAmisulpride

Acacia PharmaAPD421

Acacia PharmaAPD421- Amisulpride for IV injection

Acacia PharmaAPD421

Clinical Trials (6)

Total enrollment: 2,863 patients across 6 trials

NCT07639723 Heron TherapeuticsAprepitant Injection

Aprepitant to Improve Same Day Discharge for TKA

Start: Jul 2026Est. completion: Aug 2027350 patients

Phase 4Not Yet Recruiting

NCT00952133 EisaiPalonosetron only

Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV

Start: Jul 2009Est. completion: Apr 2011118 patients

Phase 4Completed

NCT05822713 Qilu PharmaceuticalAmisulpride

A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.

Start: Apr 2023Est. completion: Dec 2023516 patients

Phase 3Unknown

NCT02337062 Acacia PharmaAPD421

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Start: Feb 2015Est. completion: Sep 20151,147 patients

Phase 3Completed

NCT01991860 Acacia PharmaAPD421- Amisulpride for IV injection

US Phase III Study of APD421 in PONV

Start: Aug 2013Est. completion: Jan 2014364 patients

Phase 3Completed

NCT01991821 Acacia PharmaAPD421

European Phase III Study of APD421 in PONV

Start: Jul 2013Est. completion: Jan 2014368 patients

Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.